Table 4 Grade ≥3 adverse events during maintenance treatment.
BTZ cohort n = 138 | LEN cohort n = 183 | p | |
|---|---|---|---|
At least one AE grade ≥3 | 79 (57%) | 123 (67%) | 0.08 |
Neutropenia/Leukocytopenia | 3 (2%) | 79 (43%) | <0.0001 |
Anemia | – | 3 (2%) | 0.26 |
Thrombocytopenia | 6 (4%) | 19 (10%) | 0.06 |
Infections | 42 (30%) | 40 (22%) | 0.09 |
Bacterial infections (susp.) | 15 (11%) | 21 (12%) | 1.00 |
Viral infections (susp.) | 23 (17%) | 14 (8%) | 0.01 |
VZV | 14 (10%) | 7 (4%) | 0.04 |
Unknown etiology | 9 (7%) | 11 (6%) | 1.00 |
Gastrointestinal disorders | 7 (5%) | 7 (4%) | 0.59 |
Peripheral neuropathy | 12 (9%) | 3 (2%) | 0.01 |
DVT/PE | 2 (1%) | 4 (2%) | 0.70 |
Rash | 2 (1%) | 7 (4%) | 0.31 |
